Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4A | P27815 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 2/20 | 0.36 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19384838 | 0.79 | PDE4A (0.39) | PDE4ATSHRCYP2C9ALDH1A1 | |
| SCHEMBL1143744 | 0.79 | PDE4A (0.39) | PDE4ATSHRCYP2C9ALDH1A1 | |
| SCHEMBL645759 | 0.79 | PDE4A (0.39) | PDE4ATSHRCYP2C9ALDH1A1 | |
| SCHEMBL10885691 | 0.79 | PDE4A (0.39) | PDE4ATSHRCYP2C9ALDH1A1 | |
| SCHEMBL373264 | 0.79 | PDE4A (0.39) | PDE4ATSHRCYP2C9ALDH1A1 | |
| SCHEMBL23925241 | 0.79 | PDE4A (0.39) | PDE4ATSHRCYP2C9ALDH1A1 | |
| SCHEMBL5029667 | 0.78 | PDE4A (0.38) | PDE4ATSHRCYP2C9ALDH1A1 | |
| SCHEMBL1037497 | 0.76 | PDE4A (0.36) | PDE4ATSHRCYP2C9ALDH1A1 | |
| SCHEMBL23923262 | 0.76 | PDE4A (0.36) | PDE4ATSHRCYP2C9ALDH1A1 | |
| SCHEMBL1950299 | 0.76 | PDE4A (0.36) | PDE4ATSHRCYP2C9ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050255038-A1 | Conjugates comprising cancer cell specific ligands, a sugar and diagnostic agents and uses thereof | A AND D BIOSCIENCE, INC. (US) | 2005-11-17 | — | — | US | disclosed |
| US-20050215487-A1 | Conjugates comprising an nsaid and a sugar and uses thereof | HOLICK MICHAEL F | 2005-09-29 | — | — | US | disclosed |
| EP-1578402-A2 | CONJUGATES COMPRISING AN NSAID AND A SUGAR AND USES THEREOF | A & D Bioscience, Inc. (US) | 2005-09-28 | — | — | EP | disclosed |
| WO-2004002457-A2 | CONJUGATES COMPRISING AN NSAID AND A SUGAR AND USES THEREOF | A & D BIOSCIENCE, INC. (US) | 2004-01-08 | — | — | WO | disclosed |
| WO-2003086475-A1 | CONJUGATES COMPRISING CANCER CELL SPECIFIC LIGANDS, A SUGAR AND DIAGNOSTIC AGENTS, AND USES THEREOF | A & D BIOSCIENCE, INC. (US) | 2003-10-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050215487-A1 | Conjugates comprising an nsaid and a sugar and uses thereof | FUT6, FUT5, CD44 | PDE4A 1515/4885TSHR 3368/4885CYP2C9 598/4885 |
| US-20050255038-A1 | Conjugates comprising cancer cell specific ligands, a sugar and diagnostic agents and uses thereof | CD44, FUT5, FUT6 | PDE4A 4061/4885TSHR 1789/4885CYP2C9 4850/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.